Vanguard Capital Management
HCWB icon

Vanguard Capital Management’s HCW Biologics HCWB Stock Holding History

Vanguard Capital Management’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.99K Sell
2,003
-1
-0% -$6 ﹤0.01% 4051
2026
Q1 		$4.33K Buy
+2,004
New +$10.4K ﹤0.01% 4040

Other funds holding HCWB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Vanguard Capital Management's HCWB Position: Q2 2026 in Review

Vanguard Capital Management reduced its HCW Biologics (HCWB) stake by 0.05% in Q2 2026, selling an estimated $6 and leaving 2,003 shares worth $9.99K. The position accounts for ﹤0.01% of the portfolio, ranked #4051.

Vanguard Capital Management first reported a position in HCWB in Q1 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • Vanguard Capital Management held 2,003 shares of HCW Biologics worth $9.99K as of Q2 2026.
  • Vanguard Capital Management sold 1 HCW Biologics share in Q2 2026, an estimated $6.
  • HCW Biologics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4051 holding.
  • Vanguard Capital Management first reported a position in HCW Biologics in Q1 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.